drugset / Trial / NCT03381664

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664

Phase 1 Completed 17 enrolled Avanir Pharmaceuticals
RandomizedCrossoverOpen-labelBasic science

Summary

This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide \[DM\] and quinidine sulfate \[Q\] capsules) when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube, compared with administration of a capsule in healthy, fasting, adult participants.

Timeline

Start
2017-11-28
Primary completion
2018-01-30
Completion
2018-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 20 mg Oral
Subject Quinidine Small molecule 10 mg Oral

Indications

No indication recorded.